India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The company is eligible for 12 months exclusivity from launch
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
The study was conducted in patients with mild to moderate COVID-19
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Bharat Biotech expects to share further details of the trial results as additional data become available.
The programme is being implemented in collaboration with Grow Well Foundation and is expected to expand in a phased manner
The company allocated €56 million to research and development for next-generation line solutions
Subscribe To Our Newsletter & Stay Updated
